NCT00189969View on ClinicalTrials.gov

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

February 28, 2006

Conditions

Smallpox

Interventions

BIOLOGICAL

Elstree-BN

Trial Locations (1)

41460

Focus Clinical Drug Development GmbH, Neuss

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY

NCT00189969 - Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects | Biotech Hunter | Biotech Hunter